Clinical and serological manifestations associated with interferon-α levels in childhood-onset systemic lupus erythematosus

Clinics

Volumn 67, Issue 2, 2012, Pages 157-162

  Postal, Mariana ^a   Sinicato, Nailu Angé ^a   Peliçari, Karina Oliveira ^a   Marini, Roberto ^a   Costallat, Lilian Tereza Lavras ^a   Appenzeller, Simone ^a  

^a UNIVERSITY OF CAMPINAS   (Brazil)

Author keywords

Childhood onset; Interferon alpha (IFN ); SLEDAI; Systemic lupus erythematosus

Indexed keywords

ALPHA INTERFERON; ANTINUCLEAR ANTIBODY; BIOLOGICAL MARKER; GLUCOCORTICOID; PREDNISONE;

ADOLESCENT; ADULT; ARTICLE; BLOOD; CASE CONTROL STUDY; CHILD; DRUG EFFECT; FAMILY; FEMALE; HOSPITALIZATION; HUMAN; LEUKOCYTOCLASTIC VASCULITIS; LONGITUDINAL STUDY; MALE; MIDDLE AGED; PATHOLOGY; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADOLESCENT; ADULT; ANTIBODIES, ANTINUCLEAR; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CHILD; FAMILY; FEMALE; GLUCOCORTICOIDS; HUMANS; INTERFERON-ALPHA; LONGITUDINAL STUDIES; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; PREDNISONE; SEVERITY OF ILLNESS INDEX; VASCULITIS, LEUKOCYTOCLASTIC, CUTANEOUS; YOUNG ADULT;

EID: 84857665714     PISSN: 18075932     EISSN: None     Source Type: Journal    
DOI: 10.6061/clinics/2012(02)11     Document Type: Article

References (53)

1. Lee HM, Mima T, Sugino H, Aoki C, Adachi Y, Yoshio-Hoshino N, et al. Interactions among type I and type II interferon, tumor necrosis factor, and beta-estradiol in the regulation of immune response-related gene expressions in systemic lupus erythematosus. Arthritis Res Ther. 2009;11:R1, http://dx.doi.org/10.1186/ar2584.
2. Kotzin B. Systemic lupus erythematosus. Cell. 1996;85:303-306.
3. Niewold TB, Hua J, Lehman TJ, Harley JB, Crow MK. High serum IFNalpha activity is a heritable risk factor for systemic lupus erythematosus. Genes Immun. 2007;8:492-502, http://dx.doi.org/10.1038/sj.gene.6364408.
4. Brunner HI, Gladman DD, Ibañez D, Urowitz MD, Silverman ED. Difference in disease features between childhood-onset and adult-onset systemic lupus erythematosus. Arthritis Rheum. 2008;58:556-62, http://dx.doi.org/10.1002/art.23204.
5. Mina R, Brunner HI. Pediatric lupus-are there differences in presentation, genetics, response to therapy, and damage accrual compared with adult lupus? Rheum Dis Clin North Am. 2010;36:53-80, http://dx.doi.org/10.1016/j.rdc.2009.12.012.
6. Font J, Cervera R, Espinosa G, Pallarés L, Ramos-Casals M, Jiménez S, et al. Systemic lupus erythematosus (SLE) in childhood: analysis of clinical and immunological findings in 34 patients and comparison with SLE characteristics in adults. Ann Rheum Dis. 1998;57:456-9, http://dx.doi.org/10.1136/ard.57.8.456.
7. Hoffman IE, Lauwerys BR, De Keyser F, Huizinga TW, Isenberg D, Cebecauer L, et al. Juvenile-onset systemic lupus erythematosus: different clinical and serological pattern than adult-onset systemic lupus erythematosus. Ann Rheum Dis 2009;68:412-415.
8. Carreno L, Lopez-Longo FJ, Monteagudo I, Rodríguez-Mahou M, Bascones M, González CM, et al. Immunological and clinical differences between juvenile and adult onset of systemic lupus erythematosus. Lupus. 1999;8:287-292, http://dx.doi.org/10.1191/096120399678847786.
9. Hersh AO, von Scheven E, Yazdany J, Panopalis P, Trupin L, Julian L, et al. Differences in long-term disease activity and treatment of adult patients with childhood- and adult-onset systemic lupus erythematosus. Arthritis Rheum. 2009;61:13-20.
10. Sibbitt WL Jr, Brandt JR, Johnson CR, Maldonado ME, Patel SR, Ford CC, et al. The incidence and prevalence of neuropsychiatric syndromes in pediatric onset systemic lupus erythematosus. J Rheumatol. 2002;29:1536-1542.
11. Rood MJ, ten Cate R, van Suijlekom-Smit LW, den Ouden EJ, Ouwerkerk FE, Breedveld FC, et al. Childhood-onset Systemic Lupus Erythematosus: clinical presentation and prognosis in 31 patients. Scand J Rheumatol. 1999;28:222-226.
12. von Scheven E, Bakkaloglu A. What's new in paediatric SLE? Best Pract Res Clin Rheumatol. 2009;23:699-708, http://dx.doi.org/10.1016/j.berh.2009.07.008.
13. Tucker LB, Menon S, Schaller JG, Isenberg DA. Adult- and childhoodonset systemic lupus erythematosus: a comparison of onset, clinical features, serology, and outcome. Br J Rheumatol. 1995;34:866-872.
14. Appenzeller S, Marini R, Costallat LT. Damage did not independently influence mortality in childhood systemic lupus erythematosus. Rheumatol Int. 2005;25:619-624, http://dx.doi.org/10.1007/s00296-004-0552-z.
15. Rönnblom L, Alm GV. Systemic lupus erythematosus and the type I interferon system. Arthritis Res Ther. 2003;5:68-75, http://dx.doi.org/10.1186/ar625.
16. Niewold TB, Clark DN, Salloum R, Poole BD. Interferon alpha in systemic lupus erythematosus. J Biomed Biotechnol. 2010;2010:948364.
17. Hooks JJ, Moutsopoulos HM, Geis AS, Stahl NI, Decker JL, Notkins AL. Immune interferon in the circulation of patients with autoimmune disease. N Engl J Med. 1979;301:5-8.
18. Ytterberg SR, Schnitzer TJ. Serum interferon levels in patients with systemic lupus erythematosus. Arthritis Rheum. 1982;25:401-406.
19. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982;25:1271-1277, http://dx.doi.org/10.1002/art.1780251101.
20. ACR Ad Hoc Committee on Neuropsychiatric Lupus Nomencalture. The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum. 1999;42:599-608, http://dx.doi.org/10.1002/1529-0131(199904)42:4,599::AIDANR2.3.0.CO;2-F.
21. Harris EN, Gharavi AE, Patel SP, Hughes GR. Evaluation of the anticardiolipin antibody test: report of an international workshop held 4 April 1986. Clin Exp Immunol. 1987;68:215-22.
22. Brandt JT, Triplett DA, Alving B, Scharrer I, on behalf of the Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the ISTH. Criteria for the diagnosis of lupus anticoagulants: an update. Thromb Haemost. 1995;74:1185-1190.
23. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum. 1992;35:630-640.
24. Yee CS, Farewell VT, Isenberg DA, Griffiths B, Teh LS, Bruce IN, et al. The use of Systemic Lupus Erythematosus Disease Activity Index-2000 to define active disease and minimal clinically meaningful change based on data from a large cohort of systemic lupus erythematosus patients. Rheumatology (Oxford). 2011;50:982-988, http://dx.doi.org/10.1093/rheumatology/keq376.
25. Gladman DD, Urowitz MB, Goldsmith CH, Fortin P, Ginzler E, Gordon C, et al. The reliability of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index in patients with systemic lupus erythematosus. Arthritis Rheum. 1997;40:809-813, http://dx.doi.org/10.1002/art.1780400506.
26. Galley HF, Webster NR. The immuno-inflammatory cascade. Br J Anaesth. 1996;77:11-16.
27. Wozniacka A, Lesiak A, Narbutt J, McCauliffe DP, Sysa-Jedrzejowska A. Chloroquine treatment influences proinflammatory cytokine levels in systemic lupus erythematosus patients. Lupus. 2006;15:268-275, http://dx.doi.org/10.1191/0961203306lu2299oa.
28. Golding A, Rosen A, Petri M, Akhter E, Andrade F. Interferon-alpha regulates the dynamic balance between human activated regulatory and effector T cells: implications for antiviral and autoimmune responses. Immunology. 2010;131:107-117.
29. Zhang R, Xing M, Ji X, Gu L, Yang X, Wang H, et al. Interferon-alpha and interleukin-6 in SLE serum induce the differentiation and maturation of dendritic cells derived from CD34+ hematopoietic precursor cells. Cytokine. 2010;50:195-203, http://dx.doi.org/10.1016/j.cyto.2010.02.017.
30. Kim T, Kanayama Y, Negoro N, Okamura M, Takeda T, Inoue T. Serum levels of interferons in patients with systemic lupus erythematosus. Clin Exp Immunol. 1987;70:562-569.
31. Niewold TB, Adler JE, Glenn SB, Lehman TJ, Harley JB, Crow MK. Ageand sex-related patterns of serum interferon-alpha activity in lupus families. Arthritis Rheum. 2008;58:2113-2119, http://dx.doi.org/10.1002/art.23619.
32. Baechler EC, Batliwalla FM, Karypis G, Gaffney PM, Ortmann WA, Espe KJ, et al. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci U S A. 2003;100:2610-2615, http://dx.doi.org/10.1073/pnas.0337679100.
33. Kirou KA, Lee C, George S, Louca K, Peterson MG, Crow MK. Activation of the interferon-alpha pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease. Arthritis Rheum. 2005;52:1491-1503, http://dx.doi.org/10.1002/art.21031.
34. Niewold TB, Kelly JA, Flesch MH, Espinoza LR, Harley JB, Crow MK. Association of the IRF5 risk haplotype with high serum interferon-alpha activity in systemic lupus erythematosus patients. Arthritis Rheum. 2008;58:2481-2487, http://dx.doi.org/10.1002/art.23613.
35. Dall'era MC, Cardarelli PM, Preston BT, Witte A, Davis JC Jr. Type I interferon correlates with serological and clinical manifestations of SLE. Ann Rheum Dis. 2005;64:1692-1697, http://dx.doi.org/10.1136/ard.2004.033753.
36. Rönnblom L, Elkon KB. Cytokines as therapeutic targets in SLE. Nat Rev Rheumatol. 2010;6339-6347.
37. Yoo DH. Anticytokine therapy in systemic lupus erythematosus. Lupus. 2010;19:1460-1467, http://dx.doi.org/10.1177/0961203310376955.
38. Obermoser G, Pascual V. The interferon-alpha signature of systemic lupus erythematosus. Lupus. 2010;19:1012-1019, http://dx.doi.org/10.1177/0961203310371161.
39. Weckerle CE, Franek BS, Kelly JA, Kumabe M, Mikolaitis RA, Green SL, et al. Network analysis of associations between serum interferon alpha activity, autoantibodies, and clinical features in systemic lupus erythematosus. Arthritis Rheum. 2011;63:1044-1053, http://dx.doi.org/10.1002/art.30187.
40. Bastian HM, Alarcon GS, Roseman JM, McGwin G Jr, Vilá LM, Fessler BJ, et al. Systemic lupus erythematosus in a multiethnic US cohort (LUMINA) XL II: factors predictive of new or worsening proteinuria. Rheumatology (Oxford) 2007;46:683-689.
41. Sontheimer RD, Maddison PJ, Reichlin M, Jordon RE, Stastny P, Gilliam JN. Serologic and HLA associations in subacute cutaneous lupus erythematosus, a clinical subset of lupus erythematosus. Ann Intern Med 1982;97:664-671.
42. Graham RR, Kozyrev SV, Baechler EC, Reddy MV, Plenge RM, Bauer JW, et al. A common haplotype of interferon regulatory factor 5 (IRF5) regulates splicing and expression and is associated with increased risk of systemic lupus erythematosus. Nat Genet. 2006;38:550-555, http://dx.doi.org/10.1038/ng1782.
43. Rullo OJ, Woo JM, Wu H, Hoftman AD, Maranian P, Brahn BA, et al. Association of IRF5 polymorphisms with activation of the interferon alpha pathway. Ann Rheum Dis. 2010;69:611-617, http://dx.doi.org/10.1136/ard.2009.118315.
44. Bauer JW, Petri M, Batliwalla FM, Koeuth T, Wilson J, Slattery C, et al. Interferon-regulated chemokines as biomarkers of systemic lupus erythematosus disease activity: a validation study. Arthritis Rheum. 2009;60:3098-3107, http://dx.doi.org/10.1002/art.24803.
45. Garcia-Romo GS, Caielli S, Vega B, Connolly J, Allantaz F, Xu Z, et al. Netting neutrophils are major inducers of type I IFN production in pediatric systemic lupus erythematosus. Sci Transl Med. 2011;3:73ra20, http://dx.doi.org/10.1126/scitranslmed.3001201.
46. Kirou KA, Lee C, George S, Louca K, Peterson MG, Crow MK. Activation of the interferon-alpha pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease. Arthritis Rheum. 2005;52:1491-1503, http://dx.doi.org/10.1002/art.21031.
47. Shodell M, Shah K, Siegal FP. Circulating human plasmacytoid dendritic cells are highly sensitive to corticosteroid administration. Lupus 2003; 12:222-230.
48. Bennett L, Palucka AK, Arce E, Cantrell V, Borvak J, Banchereau J, et al. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J. Exp. Med. 2003;197:711-723, http://dx.doi.org/10.1084/jem.20021553.
49. Midgley A, McLaren Z, Moots RJ, Edwards SW, Beresford MW. The role of neutrophil apoptosis in juvenile-onset systemic lupus erythematosus. Arthritis Rheum. 2009;60:2390-2401, http://dx.doi.org/10.1002/art.24634.
50. Flesher DL, Sun X, Behrens TW, Graham RR, Criswell LA. Recent advances in the genetics of systemic lupus erythematosus. Expert Rev Clin Immunol. 2010;6:461-479, http://dx.doi.org/10.1586/eci.10.8.
51. Gateva V, Sandling JK, Hom G, Taylor KE, Chung SA, Sun X, et al. A large-scale replication study identifies TNIP1, PRDM1, JAZF1, UHRF1BP1 and IL10 as risk loci forsystemic lupus erythematosus. Nat Genet. 2009;41:1228-1233, http://dx.doi.org/10.1038/ng.468.
52. Sigurdsson S, Nordmark G, Göring HH, Lindroos K, Wiman AC, Sturfelt G, et al. Polymorphisms in the tyrosine kinase 2 and interferon regulatory factor 5 genes are associatedwith systemic lupus erythematosus. Am J Hum Genet. 2005;76:528-537.
53. International Consortium for Systemic Lupus Erythematosus Genetics (SLEGEN), Harley JB, Alarcón-Riquelme ME, Criswell LA, Jacob CO, Kimberly RP, et al. Genome-wide association scan in women with systemic lupus erythematosus identifiessusceptibility variants in ITGAM, PXK, KIAA1542 and other loci. Nat Genet. 2008;40:204-210, http://dx.doi.org/10.1038/ng.81.